MK-2060 + Placebo
Phase 1Completed 2 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End-Stage Renal Disease (ESRD)
Conditions
End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic
Trial Timeline
Jun 14, 2023 → Feb 15, 2024
NCT ID
NCT05769595About MK-2060 + Placebo
MK-2060 + Placebo is a phase 1 stage product being developed by Merck for End-Stage Renal Disease (ESRD). The current trial status is completed. This product is registered under clinical trial identifier NCT05769595. Target conditions include End-Stage Renal Disease (ESRD), End-Stage Kidney Disease (ESKD), Kidney Failure, Chronic.
What happened to similar drugs?
8 of 9 similar drugs in End-Stage Renal Disease (ESRD) were approved
Approved (8) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06582602 | Phase 1 | Completed |
| NCT05769595 | Phase 1 | Completed |
| NCT06843993 | Phase 1 | Completed |
| NCT05656040 | Phase 1 | Completed |
| NCT05027074 | Phase 2 | Completed |
| NCT03873038 | Phase 1 | Completed |
Competing Products
20 competing products in End-Stage Renal Disease (ESRD)